(CTRV) CEO Sapirstein Appointed to ECS BoD, BioNJ’s Board of Trustees

— Becomes Member of BIO’s Emerging Companies and Capital Formation Committees —

EDISON, N.J., June 15, 2015  — ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of ContraVir CEO James Sapirstein to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board (ECSGB) and the Capital Formation Committee. Additionally, Mr. Sapirstein has been appointed to the Board of Trustees of BioNJ, a network of approximately 400 member companies representing research-based life sciences companies and stakeholders in New Jersey.

James Sapirstein brings more than 30 years of experience in the pharmaceutical industry to BIO and BioNJ and continues to advocate support for the life sciences industry both within ContraVir’s home state and across the country.  Mr. Sapirstein last served on the BIO ECSGB and BioNJ Boards when he was CEO of Tobira Therapeutics, a biotechnology company he co-founded in 2007, where he developed successful clinical growth strategies. As a result of these and other efforts, he was named one of New Jersey’s Top 50 most influential people in healthcare in 2010 by NJBiz.

“I am honored to join both the BioNJ Board and BIO’s Emerging Companies Section Governing Board and the Capital Formation committee.  This is a great opportunity to work alongside other industry leaders to be a voice for emerging growth companies in ContraVir’s home state of New Jersey and across the rest of the country.  The Capital Formation Committee in particular works to reduce legislative barriers to capital formation, such as the creation of the JOBS Act, which is essential to encourage the growth of small emerging biotechnology companies and allows more capital to flow into the life sciences and drive innovation,” said Mr. Sapirstein.

“Through BioNJ’s and BIO’s work in areas concerning emerging growth companies, there has already been significant progress in easing these burdens, and as part of the Capital Formation committee and ECSGB at large, I hope to advance additional government policy aimed at nurturing a supportive ecosystem in which innovative biotechnology companies, such as ContraVir, can grow,” added Mr. Sapirstein.

About BIO

The Biotechnology Industry Organization (BIO) is the world’s largest trade association representing more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.  BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.  BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Emerging Companies

The BIO Emerging Companies committee serves the needs of small-to-medium size companies, most of which do not yet have major products approved and on the market.  Whether advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster biotech investment, BIO focuses on critical issues affecting smaller companies and builds programs to enhance their development.

Capital Formation

The BIO Capital Formation Committee works to review and develop policy on legislative and regulatory tax issues (including net operating loss and R&D credits, securities law issues (Sarbanes-Oxley, short selling), accounting (revenue recognition, IFRS), federal grant programs (SBIR, TIP), and other capital formation initiatives.

About BioNJ

BioNJ, The Gateway to Health, is a powerful network of 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help companies help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development.  ContraVir’s lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread^®), for the Hepatitis B virus (HBV) in Phase 2 clinical studies.  CMX157 is active against HBV and more than 4 times more potent in vitro versus tenofovir.  CMX157’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.

For further information, please contact:

Tiberend Strategic Advisors, Inc.

Tirth Patel (investors)
tpatel@tiberend.com; (212) 375-2681

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686

(ORPN) Start of a Phase 3 Study for Cabaletta in OPMD

New Pivotal Study Reflects Positive Signals Reported From the Current HOPEMD Study, Which Will Be Closed Out at 25 Patients

TEL AVIV, Israel, June 15, 2015  — BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today the start of a Phase 3 pivotal study in the USA and Canada for Cabaletta (trehalose) in Oculopharyngeal Muscular Dystrophy (OPMD).

Colin Foster, BioBlast’s President and CEO said, “We see positive signals in a consequential number of the 25 treated patients currently enrolled in our open label HOPEMD study, with respect to various muscle and other performance tests. These positive signals lead us to believe that the clinical study duration required to demonstrate efficacy may be considerably shorter than we initially predicted.

“Based upon various in vivo and cellular models of disease, we had initially expected to slow the deterioration of the disease over a period of 18 months in the HOPEMD study. Instead, we have seen evidence of improvement in a number of the functional measures within approximately the first six months.

“While we had expected that we would see a reduction in the rate of decline for these patients, we were very pleased to note in several muscle group strength tests, functional muscle tests, and the drinking test as well as several patient reported outcome measures, there were significant improvements over baseline levels. These are interim results and a randomized open label study should be cautiously interpreted. Nevertheless we are encouraged by these findings and hope to see that this positive signal continues as the study progresses.

“As a result, we have made the decision to initiate a 12 month, placebo-controlled, multi-center Phase 3 study in the next quarter that will begin enrolling approximately 60 OPMD patients in the USA and Canada into this new trial.  We have stopped enrollment in the HOPEMD trial at twenty-five patients — we had originally intended to enroll 70 patients. New OPMD patients will now be enrolled in the Phase 3 pivotal study. We anticipate that this Phase 3 study will be completed by the end of 2016, and because of its shorter duration, will provide results at the same time as the HOPEMD study.

“Consequently, we believe this new Phase 3 study will expedite our OPMD program towards a regulatory filing.”

About Oculopharyngeal Muscular Dystrophy (OPMD)

OPMD is a rare inherited myopathy characterized by dysphagia (difficulty in swallowing), the loss of muscle strength and weakness in multiple parts of the body. Patients typically suffer from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, proximal lower limb weakness, dysphonia (altered and weak voice), limitation in looking upward, facial muscle weakness and proximal upper limb weakness. The disease is most often diagnosed in the fifth-sixth decade of life and progresses throughout the patient’s life. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death.

There is no medical treatment or, to our knowledge, potential cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy and need to be repeated.

About BioBlast

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.

The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. For more information please visit the Company’s website, www.bioblast-pharma.com, the content of which is not incorporated herein by reference.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss that the required duration of our clinical trials necessary to demonstrate efficacy, the progress, design, timing, completion and announcing of results of our clinical trials, that certain clinical trials may lead to regulatory approval or that such trials may be considered pivotal, that our diverse portfolio of product candidates has the potential to address unmet medical needs for incurable genetic orphan diseases, or that our platforms potentially address unmet medical needs and offer solutions for several diseases that share the same biological pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials results. Because such statements deal with future events and are based on BioBlast Pharma’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading “Risk Factors” in BioBlast Pharma’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2015, and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: U.S. Investor Contact
         Andrew McDonald
         Founding Partner
         LifeSci Advisors, LLC
         Andrew@LifeSciAdvisors.com
         646-597-6987

(AERI) Receives Positive Feedback from FDA

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary endpoint range of its second Phase 3 registration trial of Rhopressa^TM, named Rocket 2. With this agreement, the Company is changing the primary endpoint range to include patients with baseline intraocular pressures (IOPs) ranging from above 20 mmHg (millimeters of mercury) to below 25 mmHg. The former range for the primary endpoint of above 20 mmHg to below 27 mmHg will now represent a secondary endpoint range for Rocket 2.

Highlights

• The Rocket 2 primary endpoint range is now changed to the same range where the Phase 3 registration trial results of Rocket 1 demonstrated success, ranging from above 20 mmHg to below 25 mmHg. In the Rocket 1 trial, in this range, Rhopressa^TM demonstrated non-inferiority to timolol, and numerical superiority over timolol at the majority of time points. According to the Baltimore Eye Survey, nearly 80 percent of newly diagnosed glaucoma patients have unmedicated baseline IOPs below 26 mmHg.
• The FDA also agreed that the Company may use a hierarchically-based statistical approach in determining whether this three-arm trial is adequately powered at the revised primary endpoint range. Using this methodology, the Company believes that the new primary endpoint range is adequately powered, and there is no need to recruit additional patients into Rocket 2. Three-month efficacy results for Rocket 2 are expected by the end of the third quarter of 2015.
• An additional Rhopressa^TM Phase 3 registration trial, named Rocket 4, is expected to commence in the third quarter of 2015, along with the first Roclatan^TM Phase 3 registration trial, named Mercury 1.

“We are extremely pleased with the outcome of our communications with the FDA. If Rocket 2 results resemble those of Rocket 1, we believe we may have a much greater opportunity for success in meeting the clinical endpoint of non-inferiority to timolol. We are also very appreciative of the thoughtful guidance provided by the FDA, and believe their feedback will prove very useful as our programs progress. Looking ahead, we expect to commence our next Phase 3 registration trial for Rhopressa^TM, named Rocket 4, in the third quarter of 2015. Rocket 4 is expected to be established with a primary endpoint range of above 20 mmHg to below 25 mmHg,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer.

Dr. Anido continued, “We are also preparing to commence our first Phase 3 registration trial for Roclatan^TM, named Mercury 1, in the third quarter of 2015. We believe the apparent synergies we observed in Rocket 1 for Rhopressa^TM trial patients previously on prostaglandin analogues such as latanoprost may explain why the Roclatan^TM Phase 2b results were so impressive. If successful in the Phase 3 registration trials, we believe this once-daily quadruple-action product candidate has the potential to be the most efficacious eye drop in the market for patients with glaucoma and ocular hypertension.”

Triple-Action Rhopressa™

Rhopressa^TM is a novel triple-action eye drop that we believe, if approved, would become the only once-daily product available that specifically targets the trabecular meshwork (TM), the eye’s primary fluid drain and the diseased tissue responsible for elevated IOP in glaucoma. Preclinical results have demonstrated that Rhopressa^TM also lowers episcleral venous pressure (EVP), which contributes approximately half of IOP in healthy subjects. Further, Rhopressa^TM provides an additional mechanism that reduces fluid production in the eye and therefore lowers IOP. Biochemically, Rhopressa^TM is known to inhibit both Rho Kinase (ROCK) and norepinephrine transporter (NET).

There were originally three Phase 3 registration trials for Rhopressa^TM. “Rocket 1” was a 90-day efficacy trial, the results of which were initially reported on April 23, 2015, “Rocket 2” is a 12-month safety trial with a 90-day interim efficacy readout, and “Rocket 3” is a safety-only study being conducted in Canada. In Rocket 1, for the primary endpoint range of above 20 mmHg to below 27 mmHg, Rhopressa^TM did not demonstrate non-inferiority to timolol. However, Rhopressa^TM did demonstrate non-inferiority to timolol at all ranges below 26 mmHg. As a result, the Company plans to commence in the third quarter of 2015 an additional Phase 3 registration trial, named “Rocket 4”. Based on the current clinical trial status, the Company may submit a New Drug Application filing in the second half of 2016.

Quadruple-Action Roclatan™

Roclatan™ is a once-daily eye drop that combines our triple-action Rhopressa™ with latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug. If approved, we believe that Roclatan™ would be the first glaucoma product to lower IOP through all known mechanisms: (i) increasing fluid outflow through the TM, the eye’s primary drain, (ii) increasing fluid outflow through the uveoscleral pathway, the eye’s secondary drain, (iii) reducing fluid production in the eye, and (iv) reducing EVP.

A successful 28-day Phase 2b clinical trial for Roclatan™ was completed in June 2014. Roclatan^TM achieved its primary efficacy endpoint on day 29 and demonstrated statistical superiority over the product’s individual components at all time points. We believe that Roclatan™, if approved, would be the only glaucoma product that covers the full spectrum of known IOP-lowering mechanisms, giving it the potential to provide a greater IOP-lowering effect than any currently approved glaucoma product. The first Phase 3 registration trial for Roclatan^TM, “Mercury 1,” is expected to commence in the third quarter of 2015. The Company expects to commence two additional Mercury trials in 2016.

Conference Call / Web Cast Information

Aerie management will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss the Company’s clinical trials and provide a general business update.

The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 67259440. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855)-859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 67259440. The telephone replay will be available until June 21, 2015.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company is currently conducting a Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint is to demonstrate non-inferiority of IOP lowering for Rhopressa^TM compared to timolol, along with a Phase 3 registration safety-only trial, named Rocket 3, in Canada. The Company recently completed its initial Phase 3 registration trial, named Rocket 1, the three-month efficacy results of which were initially reported in April 2015, and expects to commence a fourth Phase 3 registration trial, named Rocket 4, in the third quarter of 2015. The Company also completed in 2014 a Phase 2b clinical trial in which Roclatan^TM met the primary efficacy endpoint, demonstrating the statistical superiority of Roclatan^TM to each of its components, and plans to commence the first Phase 3 registration trial for Roclatan^TM, named Mercury 1, in the third quarter of 2015.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; our expectations regarding the commercialization of our product candidates; our expectations related to the use of proceeds from our initial public offering and the issuance and sale of our senior secured convertible notes and the issuance and sale of shares of our common stock in connection with our “at-the-market” sales agreement; our estimates regarding anticipated capital requirements and our needs for additional financing; the potential advantages of our product candidates; our plans to pursue development of our product candidates for additional indications and other therapeutic opportunities; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma; and our ability to protect our proprietary technology and enforce our intellectual property rights. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

(NETE) to Participate in St. Petersburg International Economic Forum June 19

Discussion Will Focus on Modernization of Global Payment Platforms

(RTGN) and Pulmatrix Stockholders Approve Merger

SANTA ROSA, Calif and LEXINGTON, Mass., June 12, 2015  — Ruthigen, Inc. (“Ruthigen”) (NASDAQ: RTGN) and Pulmatrix Inc. (“Pulmatrix”) today announced that at Ruthigen’s special meeting of stockholders held on June 12, 2015, Ruthigen obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Ruthigen and Pulmatrix. Pulmatrix previously obtained a sufficient number of written consents from its stockholders to consummate the merger.

Ruthigen did not obtain sufficient votes to approve the proposal to declassify its board of directors, however such approval was not required to consummate the merger.

Pursuant to the Agreement and Plan of Merger, dated as of March 13, 2015, by and among Ruthigen, Pulmatrix and Ruthigen Merger Corp., a wholly owned subsidiary of Ruthigen (“Merger Sub”), Merger Sub will merge with and into Pulmatrix (the “Merger”), with Pulmatrix surviving the Merger as a direct wholly owned subsidiary of Ruthigen.  Immediately prior to the Merger, Pulmatrix will change its name to “Pulmatrix Operating Company, Inc.” (the “Pulmatrix Name Change”) and Ruthigen will change its name to “Pulmatrix, Inc.” (the “Ruthigen Name Change”). Immediately following the Merger, the combined company will effect a 1-for-2.5 reverse stock split of its common stock (the “Reverse Stock Split”). Ruthigen and Pulmatrix made filings with the office of the Delaware Secretary of State (the “Secretary of State”) today in order to give effect to the Ruthigen Name Change, the Pulmatrix Name Change, the Reverse Stock Split and the Merger.  Subject to the acceptance of these filings by the Secretary of State, Ruthigen and Pulmatrix expect the Ruthigen Name Change, the Pulmatrix Name Change, the Reverse Stock Split and the Merger to become effective after market hours on Monday, June 15, 2015.

Subject to the aforementioned acceptance by the Secretary of State of the filings made by Ruthigen and Pulmatrix, the combined company will be named “Pulmatrix, Inc.” and expects to begin trading on NASDAQ under the symbol “PULM” at the opening of trading on June 16, 2015.

About Ruthigen

Ruthigen is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The company’s lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  For more information, visit www.ruthigen.com.

About Pulmatrix

Pulmatrix is a clinical stage biotechnology company advancing a new generation of inhaled therapeutics in a novel dry powder delivery platform. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery using particle engineering to create dry powders with unique properties: aerodynamically small, dense particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.  Pulmatrix is advancing a pipeline of products including PUR0200, a once daily inhaled bronchodilator for chronic obstructive pulmonary disease, and PUR1900, an inhaled anti-infective for the treatment of cystic fibrosis. Both PUR0200 and PUR1900 are developed using Pulmatrix’s iSPERSE technology.

IMPORTANT INFORMATION FOR INVESTORS AND STOCKHOLDERS

This release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.

The transactions contemplated by the Agreement and Plan of Merger, dated March 13, 2015, by and among Ruthigen, Pulmatrix and Merger Sub, were submitted to the stockholders of Ruthigen and Pulmatrix, respectively, for their approval. On June 12, 2015, Ruthigen’s stockholders voted on, among other things, the Merger, the proposed issuance of Ruthigen common stock in the Merger and the amendments to Ruthigen’s amended and restated certificate of incorporation to declassify Ruthigen’s board of directors and effect the Reverse Stock Split. On or about May 4, 2015, Pulmatrix mailed a consent solicitation statement to its stockholders asking them to approve the Merger. In connection with the proposed merger, Ruthigen filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that includes a consent solicitation statement of Pulmatrix and a definitive proxy statement of Ruthigen that also constitutes a prospectus. The registration statement was declared effective by the SEC on May 4, 2015, and the definitive joint proxy and consent solicitation statement/prospectus was mailed to Ruthigen and Pulmatrix stockholders on or about May 4, 2015 in connection with the Merger.

INVESTORS AND SECURITY HOLDERS OF RUTHIGEN AND PULMATRIX ARE URGED TO READ THE DEFINITIVE JOINT PROXY AND CONSENT SOLICITATION STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may currently obtain free copies of the definitive joint proxy and consent solicitation statement/prospectus, and other documents containing important information about Ruthigen filed with the SEC, through the website maintained by the SEC at www.sec.gov. Ruthigen makes copies of materials it files with, or furnishes to, the SEC available free of charge at www.ruthigen.com (in its “Investors” section), and investors and security holders may contact Ruthigen at (707) 525-9900 to receive copies of documents that Ruthigen files with or furnishes to the SEC.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Ruthigen and Pulmatrix caution that such statements involve risks and uncertainties that may materially affect Ruthigen’s and Pulmatrix’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the possibility that the proposed transaction does not close when expected or at all because required approvals are not received on a timely basis; the risk that the benefits from the proposed transaction may not be fully realized or may take longer to realize than expected; the ability to promptly and effectively integrate the businesses of Ruthigen and Pulmatrix; the ability to realize anticipated synergies and cost savings from the transaction; the reaction of the companies’ customers, employees and counterparties to the transaction; diversion of management time on transaction-related issues; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital; and the ability to secure and enforce legal rights related to the companies’ products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Ruthigen and Pulmatrix, is set forth in the registration statement on Form S-4 filed by Ruthigen on April 15, 2015, as amended. Ruthigen and Pulmatrix disclaim any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

(CRME) Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion

NASDAQ: CRME     TSX: COM

VANCOUVER, June 12, 2015  – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that an independent study conducted by investigators at the University of Leipzig Heart Center, Germany, found that intravenous vernakalant facilitated successful electrical cardioversion (“ECV”) in patients who had failed to attain sinus rhythm (“SR”) following failed electrical cardioversion (“FECV”), or who immediately returned to Atrial Fibrillation (“IRAF”) after briefly attaining SR. The study, entitled “Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion” authored by Andreas Müssigbrodt et al., is published in the Advanced Access section of journal Europace website (June 8, 2015). Cardiome Pharma Corp. did not fund the study, design its protocols or have any role in study implementation or analysis.

The non-randomized study examined if either of two pharmacologic converting agents, vernakalant or amiodarone, facilitated subsequent ECV in 63 patients with IRAF (n = 44; 70%) or FECV (n = 19; 30%) after consecutive ECV. Patients were assigned to receive either a single dose of vernakalant (n = 33; 52%) or amiodarone (n = 30; 48%) prior to another attempt with ECV at the discretion of the treating physician. Ten minutes after completion of the drug infusion, transthoracic ECV was attempted again with a shock that had the same energy as the previous shock. In the event of another episode of IRAF, no more attempts of ECV were repeated.

The study found that 66.7% of the patients in the vernakalant group (22 of 33 patients) were successfully electrically cardioverted after drug infusion compared to 46.7% (14 of 30 patients) of patients treated with amiodarone (P=0.109). Treatment with vernakalant was also listed as a predictor of successful, drug-facilitated ECV based upon the results of a multivariate analysis (OR 0.057, 95% CI 0.006-0.540, P=0.013). In addition, a subgroup analysis found that patients who had undergone previous AF ablation and who were provided vernakalant had a conversion rate of 66.7% (6 of 9 patients) compared to 11.1% (1 of 9 patients) in the same population who were provided amiodarone (P=0.016).  The authors concluded that vernakalant “may therefore be considered as a useful agent for facilitated ECV in cardioversion resistant AF.” The study did not report any major adverse events.

“We are very excited to see the results from this small non-randomized study in a resistant patient population but larger, controlled clinical studies will be necessary to confirm its findings,” said Dr. Steen Juul-Möller, Cardiome’s Medical Director. “These results underline the vernakalant -induced stabilizing effect on the atrial wavelets in Atrial Fibrillation, facilitating cardioversion even in patients with AF relapse after lung vein isolation ablation.” In addition, Dr. Juul-Möller commented that “Taken together with the independent data published earlier this year suggesting that challenging post-surgical patients also received a benefit from vernakalant, this new data within resistant patients suggests that physicians who are using vernakalant in their clinical practice show continued high interest to explore its use by expanding scientific evidence.”

About the Study¹
Between November 2011 and May 2014, 63 patients (66.7% males) who had initially failed to attain SR with transthoracic ECV, or who failed to remain in SR after briefly converting, were infused with either vernakalant or amiodarone prior to another attempt to electrically cardiovert the patient. The primary end-point was acute successful ECV into sinus rhythm after drug facilitated ECV.

Sixty-seven percent (66.7%) of patients provided vernakalant successfully converted with pharmacologically facilitated ECV compared to 46.7% of amiodarone treated patients. IRAF recurrence was observed in 24.2% of the vernakalant treated patients compared to 36.7% of patients treated with amiodarone (P=0.283). FECV occurred in 9.1% of vernakalant-treated patients compared with 16.7% of amiodarone-treated patients (P = 0.271). Additional results and analyses are available within the study. There were no major adverse events. Three patients (9.1%) in the vernakalant group described transient tingling paraesthesia in their upper body versus 0% in the amiodarone group. QT prolongation over 500ms or QRS widening >50% was not observed in either group. There were no incidences of atrial flutter.

The authors concluded that vernakalant may be considered as a useful agent for facilitated ECV in cardioversion resistant AF.

References:
1.   Müssigbrodt A., et al. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace. doi:10.1093/europace/euv194. First published online: June 8, 2015.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS^TM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2015 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

(FOLD) Prices Underwritten Offering of Common Stock

CRANBURY, N.J., June 11, 2015  — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. The offering is expected to close on June 17, 2015, subject to customary closing conditions.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as lead manager and Janney Montgomery Scott LLC is acting as co-manager for the offering.

The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold™ (migalastat) for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.

The securities described above are being offered by Amicus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the “SEC”). A prospectus supplement relating to the offering will also be filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204) or Goldman, Sachs & Co., by mail, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile: 212-902-9316, by email: prospectus-ny@ny.email.gs.com; or by telephone: 866-471-2526.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. Amicus’ lead programs in development include the small molecule pharmacological chaperone Galafold™ for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I.

Forward-Looking Statements

Statements in this press release concerning Amicus’ future expectations, plans and prospects, including, without limitation, statements regarding the proposed public offering, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to various risks, uncertainties and important factors, including those set forth in the “Risk Factors” section in the prospectus supplement relating to the offering and in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission, any of which could cause its actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

FOLD–G

CONTACT: Investors/Media:
         Amicus Therapeutics
         Sara Pellegrino
         Director, Investor Relations
         spellegrino@amicusrx.com
         (609) 662-5044

         Media:
         Pure Communications
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085

(SYN) First Participant Dosed in Second Phase 2a Clinical Trial

— Study to Evaluate SYN-004’s Antibiotic-Degrading Effect in the Gut in the Presence of Esomeprazole —

ROCKVILLE, Md., June 12, 2015  — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, dosed the first participant in a second Phase 2a clinical trial of SYN-004. This trial will evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, in the presence of the proton pump inhibitor (PPI), esomeprazole. SYN-004 is the Company’s candidate therapy designed to degrade certain intravenous (IV) beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and secondary antibiotic-resistant infections.

C. difficile is the leading type of hospital acquired infection and is frequently associated with IV antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone. However, antibiotics have the potential to cause unintended harmful effects within the GI tract, including disruption of the natural balance of the gut microbiome, leading to 1.1 million C. difficile infections^[i] and 30,000 C. difficile-related deaths^[ii] in the United States each year.

PPIs are often used prophylactically in hospitalized patients. Therefore, with guidance from the U.S. Food and Drug Administration (FDA), Synthetic Biologics is conducting this study to demonstrate the ability of SYN-004 to degrade an intravenous (IV) antibiotic in the presence of a PPI.

“As participants complete the first Phase 2a clinical trial of SYN-004, they have the option to continue the evaluation of SYN-004 by moving into this second Phase 2a clinical trial,” stated Joseph Sliman, M.D., M.P.H., Senior Vice President, Clinical & Regulatory Affairs of Synthetic Biologics. “Collecting data in this second Phase 2a trial allows us to build a pharmacokinetics (PK) model, a valuable tool when other antibiotics are evaluated in the future. We want to clearly demonstrate the ability of SYN-004 to degrade antibiotics in the gut, to protect the microbiome from the damaging effects of antibiotics and dramatically reduce C. difficile infections through prevention vs. treatment. We remain on track to complete and report preliminary data from the first Phase 2a clinical trial within the month, and to initiate the Phase 2b clinical trial in the third quarter of this year.”

This second Phase 2a multi-center, open-label, 2-period, fixed-sequence study is expected to evaluate the ability of SYN-004 to degrade residual IV ceftriaxone in the GI tract in the presence of a PPI  in up to 20 healthy participants with functioning ileostomies. The study consists of two treatment periods for all participants: 1) the administration of SYN-004 and IV ceftriaxone, and 2) the administration of SYN-004 and IV ceftriaxone in the presence of esomeprazole, an approved, over-the-counter PPI. Chyme samples will be collected from the participants to measure the ability of SYN-004 to degrade the residual antibiotic. Participants are expected to be enrolled at up to four trial sites located in the United States and Canada.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection (Phase 2a) and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the potential of SYN-004 degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, the anticipated timing of the reporting of preliminary data from the Phase 2a clinical trial and the timing of initiation of the Phase 2b clinical trial and the potential market for SYN-004. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics’ therapeutics, a failure of Synthetic Biologics’ clinical trials, and those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure of Synthetic Biologics’ clinical trials to receive anticipated funding, a failure of Synthetic Biologics’ products for the prevention and treatment of diseases to be successfully developed or commercialized, Synthetic Biologics’ inability to maintain its licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

(IKAN) Presenting in TNO’s Ultra-Fast-Broadband Seminar

Ikanos Expert Will Discuss Framework to Facilitate Self-Install by the Subscriber for Future Deployments of G.fast and Vectored VDSL2 Services

(MYOS) Publishes Research Article Highlighting Fortetropin® Proteo-Lipid Complex Benefits

(GSOL) Announces Intended Cash Tender Offer Up To $50 Million

NEW YORK, June 11, 2015  — Global Sources Ltd. (NASDAQ: GSOL) intends to commence an issuer tender offer by the end of June 2015, with expected completion before the end of July 2015, for up to 6,666,666 shares, or approximately 22.05% of its outstanding common shares as of April 30, 2015, at a purchase price of $7.50 per share in cash. Global Sources expects to fund the tender offer with cash on hand. As of March 31, 2015, Global Sources had total cash, cash equivalents and available-for-sale securities of approximately $103.6 million.

The offer will afford tendering shareholders liquidity for some or all of their shares and will permit them to have their shares repurchased at a 16.82% premium over the closing price per share of $6.42 on June 10, 2015, the last full trading day before the date of this announcement. Shareholders who elect not to tender their shares in the offer will increase their relative percentage ownership in Global Sources following completion of the offer.

Global Sources’ executive chairman, Merle A. Hinrich, said: “I am pleased to announce that after carefully considering all of the options to return capital to the shareholders, the Board of Directors has approved a tender offer as the most efficient alternative at this time. We believe this measure reflects our continued commitment to enhancing shareholder value and enables all shareholders to participate equally in a return of investment, if so chosen. At the close of the transaction, Global Sources will still have a strong balance sheet, giving us the financial strength to pursue our growth initiatives and other options to invest in the business.”

Global Sources has been informed that its Directors and Officers who own shares can be expected to tender all or a portion of their shares in the offer. Such Directors and Officers beneficially owned approximately 47.80% of Global Sources’ outstanding common shares as of Feb. 28, 2015.

THIS PRESS RELEASE CONSTITUTES NEITHER AN OFFER TO BUY NOR THE SOLICITATION OF AN OFFER TO SELL SHARES. THE SOLICITATION AND THE OFFER TO BUY GLOBAL SOURCES’ COMMON SHARES WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS THAT GLOBAL SOURCES EXPECTS TO BEGIN DISTRIBUTING TO ITS SHAREHOLDERS BY THE END OF JUNE 2015. SHAREHOLDERS SHOULD READ THESE MATERIALS CAREFULLY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING VARIOUS TERMS AND CONDITIONS OF THE OFFER. SHAREHOLDERS WILL BE ABLE TO OBTAIN FOR FREE THE OFFER TO PURCHASE AND OTHER FILED DOCUMENTS AT THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV. ONCE AVAILABLE, THESE DOCUMENTS MAY ALSO BE OBTAINED FOR FREE IN THE INVESTOR RELATIONS SECTION OF GLOBAL SOURCES’ WEBSITE AT GLOBALSOURCES.COM.

About Global Sources

Global Sources is a leading business-to-business media company and a primary facilitator of trade with Greater China.

The core business facilitates trade between Asia and the world using English-language media such as online marketplaces (GlobalSources.com), print and digital magazines, sourcing research reports, private sourcing events, and trade shows.

More than 1 million international buyers, including 95 of the world’s top 100 retailers, use these services to obtain product and company information to help them source more profitably from overseas supply markets. These services also provide suppliers with integrated marketing solutions to build corporate image, generate sales leads and win orders from buyers in more than 240 countries and territories.

Global Sources’ other businesses provide Chinese-language media to companies selling to and within Greater China. These services include online web sites, print and digital magazines, seminars and trade shows. In mainland China, Global Sources has a network of more than 30 office locations and a community of more than 5 million registered online users and magazine readers of its Chinese-language media.

Now in its fifth decade, Global Sources has been publicly listed on the NASDAQ since 2000.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27-A of the Securities Act of 1933, as amended and Section 21-E of the Securities Exchange Act of 1934, as amended. The company’s actual results could differ materially from those set forth in the forward-looking statements as a result of the risks associated with the company’s business, changes in general economic conditions, and changes in the assumptions used in making such forward-looking statements.

(DRAM) ransformation Begins Delivering Improved Sales Performance

Company Intends to Build on Recent Successes

PRINCETON, N.J., June 11, 2015  — Dataram Corporation (NASDAQ: DRAM) announced today that it has started to recognize improvements in sales activity that directly correlate with the company’s aggressive transformation to improve its market position, and return the company to profitability.

As part of the transformation, Dataram reset the business strategy, added new sales talent, realigned the global sales team, deployed a new CRM solution, and developed and communicated a new value proposition to business partners and customers. The company also engaged partners to extend its sales operations into geographies and segments where Dataram does not have an active presence, and assist the company further penetrate principal territories and segments where it has a presence.

As a direct result of Dataram’s “Care, Consult, and Customize” approach, and collaboration with partners, Dataram has had several recent successes which have reaffirmed its efforts and improved its market position.  Dataram acquired a new strategic customer in the digital communications industry. This customer is a world leader in 3G, 4G and next-generation wireless technologies. With fully customizable and flexible memory hardware and services solution, this customer realized an estimated savings of $300-$500K on an anticipated spend of $1.5M.  In addition, based on Dataram’s reputation as a reliable provider to the energy sector, the company won a strategic opportunity at a leading oil and gas producer in the U.S.A., where third-party memory had not been previously considered.  The customer recognized significant savings using the Dataram solution.  Dataram has also successfully expanded its relationships with enterprise and business partners alike in both Europe and the Middle East.

“The ability of Dataram’s sales team to provide value and savings to enterprise and OEM customers through unique memory solutions and personalized attention has produced results that we continue to build upon,” said Phil Marino, Dataram’s VP Global Sales.  “We recently added a new strategic channel partner in the US and re-engaged with one of Europe’s largest value-added distributors.  Our pipeline continues to grow and is the strongest it’s been in years.  We are in active discussions with several additional partners in the US and EMEA.  Our renewed focus on the memory business is paying off and our best times are ahead.”

“Our efforts are beginning to deliver quantifiable results as demonstrated through recent wins and growing pipeline,” added Dave Moylan, Dataram’s Chairman and CEO.  “Our sales team and partners are, and will continue to be, an integral role of the company’s growth strategy.  We look forward to continuing to work with them to build on recent successes as we reignite the market’s passion for Dataram’s solutions.”

About Dataram Corporation
Dataram is a leading independent manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstation, desktops and laptops sold by leading manufacturers such as Dell, Cisco, Fujitsu, HP, IBM, Lenovo and Oracle. Dataram’s memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Additionally, Dataram manufactures and markets a line of Intel Approved memory products for sale to manufacturers and assemblers of embedded and original equipment. 70 Fortune 100 companies are powered by Dataram. Founded in 1967, the company is a US based manufacturer, with presence in the United States, Europe and Asia. For more information about Dataram, visit www.dataram.com.

All names are trademarks or registered trademarks of their respective owners.

The information provided in this press release may include forward-looking statements relating to future events, such as the development of new products, pricing and availability of raw materials or the future financial performance of the company. Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products and other factors described in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.  The company has based these forward-looking statements on its current expectations and assumptions about future events.  While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the company’s control.  The company does not assume any obligations to update any of these forward-looking statements.

Dataram Contact:
Jeffrey Goldenbaum
Director, Marketing
609.799.0071
info@dataram.com

(CJJD) Online Sales Achieved Over 90% Growth in FY 2015

HANGZHOU, China, June 11, 2015  — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company”, “China Jo-Jo”, “Our” or “We”) is a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its online and retail pharmacies, today announced that, based on the Company’s preliminary data, annual sales from the Company’s online pharmacy grew at least 90% year over year with an over 200% increase from its own online pharmacy site and annual sales from its offline drugstores grew by more than 20% in the year ended March 31, 2015. For the first time in the Company’s history, online pharmacy sales reached approximately US$14 million in fiscal year2015, accounted for over 18% of its total annual revenue, as compared to about 11% in fiscal year 2014.

Since 2013, China Jo-Jo’s management team has been directing their focus towards building and expanding its online pharmacy business in China, with ultimate goals to support long term organic growth, improve profit margin and enhance shareholders’ return. The preliminary result from our online pharmacy division, which exceeds the Company’s internal projection of $13 million, reflected our balanced strategy of collaboration with third-party B2C e-commerce partners, such as Taobao, JD.com and Amazon.com, while building our own online pharmacy brand, www.dada360.com. During the fiscal year 2015, our business was also positively impacted by new initiatives, such as close cooperation with certain large commercial insurance companies in China, partnership with Shanghai Jianbao Technology Co., Ltd. (“Shanghai Jianbao”), a leader in China’s Pharmacy Benefit Management (PBM) sector, as well as the launching of Alipay service, China’s dominant mobile payment system, to our customers.  China Jo-Jo expects the growth in its online pharmacy division will continue in the current fiscal year and beyond.

The Company is currently working closely with its newly engaged independent auditing firm, BDO China Shu Lun Pan Certificated Public Accountants LLP (“BDO China”) to complete its annual report for the fiscal year 2015.Managementanticipates filling the annual report with the Securities Exchange Commission on or before June 29, 2015.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of March 31, 2015, the Company had 59 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “estimate,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

(NETE) SeeThruEquity Issues Company Update, Highlights New Products & Partnerships

NEW YORK, NY / June 11, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Net Element, Inc. (NASDAQ: NETE).

The note is available here: NETE Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“Net Element has achieved several important developments since our last update in March 2015. Most importantly, Net Element made substantial progress shedding cumbersome debt on its balance sheet and announced a new $24.5mn capital raise. While improving its financial position, the company also reported double-digit annual growth in both 1Q15 and fiscal 2014 results and announced several growth initiatives for 2015 and beyond. The company also announced that it had executed definitive documentation for the acquisition of PayOnline, a leader in online transaction processing services and payment technology with over 10mn active consumers and thousands of merchants in the Russian Federation, Europe and Asia. We are reiterating our 12 month price target on NETE of $5.17 per share,” stated Ajay Tandon, CEO of SeeThruEquity.

Additional highlights of the note are as follows:

Recent results show continued growth

Net Element reported 1Q15 and fiscal 2014 results that demonstrated continued growth and reduced losses. 1Q15 revenues of $5.5mn were up approximately 15% from $4.8mn in 1Q14, with YoY growth rates accelerating from 13% annual growth in 2014. Net loss narrowed from ($3.6mn) in 1Q14 to ($2.2mn) in 1Q15, with 1Q15 EPS improving to ($0.05). This was a continuation of improving profitability for the company, as fiscal 2014 EPS narrowed to ($0.27) versus ($1.70) in the year ago period.

Improved balance sheet a platform for future development

We have been impressed at Net Element’s ability to grow its top line at double-digit percentages while de-leveraging financial risk. Over the last five quarters the company has reduced debt outstanding from approximately $31mn at the end of fiscal 2013 to just $4.1mn at the end of 1Q15. Further, Net Element announced a key strategic financing on May 1, 2015. Net Element entered into an agreement to raise up to $24.5mn in two transactions comprising a mix of Series A 9% Preferred Stock and convertible debt plus warrants. We see the announcement as a significant milestone for the company – one that we believe enabled the acquisition of mobile payment technology innovator PayOnline, while also providing growth capital.

New products and partnerships set the stage for growth

Net Element also announced several partnerships, which we believe have the potential to accelerate growth. First the company formed a joint venture in the UAE, New Elements LLC, in which UAE-based partners will finance the company in exchange for access to market Net Element’s technology and brand name in Indian and the GCC region. Net Element will hold a 20% interest in the JV, providing upside potential without drawing resources from the company’s core business. The company also announced a technology partnership with Italy-based TAS Group to develop Europay, Mastercard and Visa (EMV) chip enabled solutions, card management systems, and mobile payment systems for the US and Latin America, as well as a merchant portfolio financing deal with RBL Capital, which should allow its sales partners to accelerate their market penetration.

Please review important disclosures on our website at www.seethruequity.com.

About Net Element, Inc.

Net Element (NASDAQ: NETE) is a global payments-as-a-service, technology provider with an integrated mobile and transactional services platform serving millions of emerging market clients. Its wholly owned subsidiary, TOT Group operates Unified Payments, a U.S. focused transaction processing and value-added services brand, Aptito, a next generation, cloud-based point of sale payments platform and TOT Money, a leading mobile payments service provider that is gaining significant traction in the mobile payments market in Russia and for two consecutive years, has been ranked in the Top 3 mobile payments providers by Beeline, Russia’s second largest telecommunications operator.

Further information is available at www.netelement.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

(VNET) Announces Change in Leadership Team

BEIJING, June 10, 2015  — 21Vianet Group, Inc. (Nasdaq:VNET) (“21Vianet” or the “Company”), a leading carrier-neutral internet data center services provider in China, today announced that Mr. Frank Meng, the president of the Company, will be leaving the Company to pursue other opportunities, effective immediately.

Mr. Josh Chen, Founder, Chairman and Chief Executive Officer of the Company, stated, “Mr. Meng has made an important contribution to 21Vianet since he joined us in July 2013. We thank him for his leadership and dedication to the Company. We wish him all the best in his future endeavors.”

Mr. Meng’s responsibilities have been delegated to and shared among 21Vianet’s existing senior management team.

About 21Vianet

21Vianet Group, Inc. is a leading carrier-neutral internet data center services provider in China. 21Vianet provides hosting and related services, managed network services, cloud services, content delivery network services, last-mile wired broadband services and business VPN services, improving the reliability, security and speed of its customers’ internet infrastructure. Customers may locate their servers and networking equipment in 21Vianet’s data centers and connect to China’s internet backbone through 21Vianet’s extensive fiber optic network. In addition, 21Vianet’s proprietary smart routing technology enables customers’ data to be delivered across the internet in a faster and more reliable manner. 21Vianet operates in more than 30 cities throughout China, servicing a diversified and loyal base of more than 2,000 customers that span numerous industries ranging from internet companies to government entities and blue-chip enterprises to small- to mid-sized enterprises.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. 21Vianet may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Further information regarding these and other risks is included in 21Vianet’s reports filed with, or furnished to, the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and 21Vianet undertakes no duty to update such information, except as required under applicable law.

CONTACT: Investor Relations Contact:

         21Vianet Group, Inc.
         Eric Chu, CFA
         +1 (908) 707 2062
         IR@21Vianet.com

         Joseph Cheng
         +86 10 8456 2121
         IR@21Vianet.com

         ICR, Inc.
         Calvin Jiang
         +1 (646) 405-4922
         IR@21Vianet.com

(HRTX) Announces Pricing of Underwritten Offering of Common Stock

Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $24.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about June 15, 2015, subject to customary closing conditions. Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC are acting as joint book-runners for the offering. JMP Securities LLC, Brean Capital, LLC and Noble Life Science Partners are acting as co-managers for the offering.

The gross offering size will be approximately $119 million before deducting customary underwriting discounts and commissions and offering expenses. Heron Therapeutics, Inc. intends to use the net proceeds from the underwritten offering primarily for general corporate purposes, which include, but are not limited to, the commercial launch of SUSTOL® (granisetron injection, extended release), if approved, funding the company’s ongoing and future clinical trials, preclinical development work, and for general and administrative expenses, or other product development activities.

The securities described above are being offered pursuant to shelf registration statements (File Nos. 333-195928 and 333-198862), which were declared effective by the United States Securities and Exchange Commission (“SEC”) on May 23, 2014 and October 6, 2014, respectively. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering can be made only by means of a prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.

Investor Relations Contact:
Heron Therapeutics, Inc.
Jennifer Capuzelo, 858-703-6063
Sr. Manager, Investor Relations
jcapuzelo@herontx.com
or
Corporate Contact:
Heron Therapeutics, Inc.
Brian Drazba, 858-703-6065
Vice President, Finance and Chief Financial Officer

(VCEL) Announces Plan to Submit Biologics License Application to FDA

CAMBRIDGE, Mass., June 10, 2015  — Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug Administration (FDA) the company plans to submit a Biologics License Application (BLA) to the FDA by the end of 2015 for MACI™ for the treatment of focal chondral cartilage defects in the knee.

“We have had very productive discussions with the FDA regarding the regulatory pathway for the submission of the MACI BLA in the United States,” said David Recker, MD, chief medical officer of Vericel. “Our planned MACI BLA submission reflects Vericel’s commitment to deliver innovative therapies for patients with serious cartilage injuries in the knee.”

MACI (matrix-applied characterized autologous cultured chondrocytes) is a third-generation autologous chondrocyte implantation (ACI) product for the treatment of cartilage defects in the knee. MACI was the first tissue-engineered product approved under the Advanced Therapy Medicinal Product guidelines by the European Commission. The pivotal Phase 3 clinical trial supporting MACI registration in Europe (the Superiority of MACI Implant to Microfracture Treatment, or SUMMIT study) demonstrated a statistically significant and clinically meaningful improvement in the co-primary endpoint of pain and function for patients treated with a MACI implant compared to microfracture at two years.

About Vericel Corporation

Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel^® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel^® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company’s website at www.vcel.com.

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products and growth in revenues, intended product development, clinical activity timing, integration of the acquired business, and objectives and expectations regarding our company described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “we believe,” “we intend,” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “potential,” “could,” “may,” or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory submission and approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues and perceived market demand for our products. These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2015, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management’s current views and Vericel does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Investors:
         Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947
         or
         Lee Stern
         The Trout Group
         lstern@troutgroup.com
         (646) 378-2922

         Media:
         Bill Berry
         Berry & Company
         bberry@berrypr.com
         (212) 253-8881

(DSKX) DS Healthcare Group’s Integra Revealed

Pompano Beach Fla., June 10, 2015  — DS Healthcare Group, Inc. (NASDAQ:DSKX). The Integra over-the-counter tablet for thinning hair and improved hair health is now here. The first reveal image can be seen on this link: http://dshairclinic.com/letters/Integra.png

It is the world’s first tablet that contains Astressin-B along with a combination of other novel compounds. This product is the result of findings from DS Healthcare Group’s ongoing research on hair loss and related conditions. Astressin-B is a complex peptide that has shown in landmark research that it can reduce the effects of Corticotropin-releasing hormone (CRH) involved in the stress response. CRH is associated with many other diseases and is also believed to have a direct impact on hair health.

“We are extremely excited about this new treatment option. Integra is revolutionary and unlike anything else currently available. All other supplements are based on ordinary vitamins and minerals which have no known mechanism for efficacy. We expect strong results in markets where oral tablets are popular and expect a high clinical acceptance among doctors,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. (DSKX) leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, salons and pharmacies. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

Abner Silva
DS Healthcare Group
407.342.4112
Abner@DSHealthgroup.com

(RCON) Becomes a Qualified Contractor for Sinopec Subsidiary

BEIJING, June 10, 2015  — Recon Technology, Ltd. (NASDAQ: RCON), (“Recon” or the “Company”), a leading independent oilfield services provider operating primarily in China, today announced that the Company has received Contractor (Subcontractor) Qualification (the “Qualification”) from Jianghan Oilfield Construction Engineering Company (“JOCEC”), a subsidiary of China Petroleum & Chemical Corporation (NYSE: SNP) (“Sinopec”). The Qualification, which is valid for one year from June 4, 2015 and extendable on a yearly basis thereafter, qualifies Recon as a general contractor (subcontractor) to participate in certain construction and engineering projects at JOCEC ranging from the expansion and renovation of existing facilities to the construction of new facilities.  In connection with the Qualification, the Company also announced today that it has secured a contract with JOCEC worth approximately RMB 550,000.

Mr. Shenping Yin, Chairman and Chief Executive Officer of Recon, commented, “The Qualification, combined with the entry permit awarded by JOCEC earlier this year, clears the path for our increasing presence at JOCEC and sets the stage for a broader and deeper relationship with Sinopec’s subsidiaries, that collectively have contributed 19.6% of our total revenues in fiscal year 2014.”

About Sinopec and JOCEC

Founded in 2000 and headquartered in Beijing, China Petroleum & Chemical Corporation (“Sinopec”) is one of the largest integrated energy and chemical companies in China. Its principal operations include the exploration and production, pipeline transportation and sale of petroleum and natural gas; the sale, storage and transportation of petroleum products, petrochemical products, coal chemical products, synthetic fiber, fertilizer and other chemical petroleum, natural gas, petroleum products, petrochemical and chemical products, and other commodities and technologies; and research, development and application of technologies and information.

Sinopec Jianghan Oilfield Construction Engineering Company (“JOCEC”) is a wholly-owned subsidiary of Sinopec and a full-service oilfield construction and service company primarily serving the production facilities managed by Sinopec.

About Recon Technology, Ltd.

Recon Technology, Ltd. is China’s first independent oil and gas field service company listed on NASDAQ. Closely working with leading global partners, Recon has achieved rapid growth supplying China’s largest oil and gas exploration companies, including Sinopec and China National Petroleum Corporation, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measures. The solutions Recon provides are aimed at increasing gas and petroleum extraction levels, reducing impurities, improving safety and lowering production costs. For additional information, please visit: www.recon.cn.

Cautionary Statements

Statements made in this release with respect to Recon’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Recon. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. Recon cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. Therefore investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements. 

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:    

Recon Technology, Ltd.
Tel: +86-10-8494-5799
Email: info@recon.cn
Web: http://www.recon.cn

Weitian Investor Relations
Tina Xiao
Tel: +1-917-609-0333
Email: tina.xiao@weitian-ir.com

(OGEN) & (XON) Expand Collaboration to Pursue Development of Biotherapeutics

Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Oragenics (NYSE MKT:OGEN), today announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic™ AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.

“We are eager to advance therapeutic programs through the established clinical foundations of the ActoBiotics™ platform, and moving forward in the clinic with AG013 is a natural fit for our focus on the treatment of oral cavity diseases with innovative biopharmaceuticals,” said Frederick Telling, Ph.D., Chairman of the Board of Oragenics. “Work continues under our current collaboration with Intrexon centered on the development of a novel class of antibiotics known as lantibiotics, and we are excited to build on this relationship in the field of oral health to realize the promise of microbial approaches in the generation of efficacious new medicines.”

“I am pleased that this new collaboration provides an opportunity for continued development of AG013 as an intervention for oral mucositis,” said Stephen T. Sonis, DMD, DMSc, Senior Surgeon, Divisions of Oral Medicine, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. “AG013’s successful attenuation of chemotherapy-induced oral mucositis in the Phase 1B trial suggests that this innovative delivery platform may offer a new approach to the treatment of this important unmet clinical need.”

Through the molecular engineering of food-grade microbes (Lactococcus lactis), biologically-contained ActoBiotics™ allow for in situ expression and secretion of novel biotherapeutic proteins and peptides. AG013 is formulated as a convenient oral rinsing solution and designed to deliver the therapeutic molecule Trefoil Factor 1 (TFF1) to the mucosal tissues in the oral cavity. TFFs are a class of peptides that are involved in protection of the gastrointestinal tissues against mucosal damage and have an important role in subsequent repair.

A phase 1B clinical trial with AG013 in 25 cancer patients with OM across 5 cancer referral centers showed that AG013 was safe and well tolerated. Data published in the journal Cancer showed a 35% reduction of the duration of ulcerative OM in the AG013-treated patients versus the placebo-treated patients. Furthermore, close to 30% of the patients treated with AG013 were full responders while all placebo-treated patients developed ulcerative OM. Additionally, a phase 1 pharmacokinetic (PK) study in 10 healthy volunteers showed that live AG013 bacteria adhere to the buccal mucosa and actively secrete protein locally, resulting in homogeneous exposure to the entire mucosal surface up to 24 hours after administration of a rinse. AG013 has already been granted Orphan Drug status in the European Union and has potential eligibility for Biologic License Application exclusivity as well as Fast Track designation with the United States Food and Drug Administration.

Under the terms of the agreement, Oragenics will have access to Intrexon’s technologies and expertise to develop products for the treatment of oral mucositis or products containing genetically modified Lactococcus lactis expressing trefoil factors in the oral cavity, throat, and esophagus for a technology access fee and will reimburse Intrexon for the research and development costs. The agreement also provides for commercial and regulatory milestone payments to Intrexon, as well as a low double-digit percentage royalty based on the net sales from collaboration products.

“AG013 represents a promising product from a truly innovative platform for the prevention of oral mucositis in cancer patients,” commented Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon’s Health Sector. “We are very pleased with the expanded collaboration with Oragenics, especially given their unique experience in the field of oral health using novel approaches. This ECC will further the clinical development of AG013 in the hope of providing cancer patients with a much needed adjunctive therapy for oral mucositis, a challenging side effect that can become a treatment-limiting toxicity for effective cancer therapy.”

About Intrexon Corporation

Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA^™ to create biologically-based products that improve the quality of life and the health of the planet. The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA^®, and we invite you to discover more at www.dna.com.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has previously established two exclusive worldwide channel collaborations with Intrexon Corporation Inc. (XON), a synthetic biology company. The collaborations will allow Oragenics access to Intrexon’s proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States.

Trademarks

Intrexon, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

(NETE) Includes Apple Pay(TM) in New Version of Aptito

Competitive Features and Pricing Appeals to Independent Restaurant Segment

(CMGE) Enters Into Definitive Merger Agreement

HONG KONG, June 9, 2015  — China Mobile Games and Entertainment Group Limited (“CMGE” or the “Company”) (Nasdaq:CMGE), the largest publisher and a leading developer of mobile games in China, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Pegasus Investment Holdings Limited (“Parent”) and Pegasus Merger Sub Limited (“Merger Sub”), pursuant to which Parent will acquire CMGE (the “Transaction”) for US$1.5714 per Class A or Class B ordinary share, or US$22.00 per American depositary share, each representing 14 Class A ordinary shares (“ADSs”).

Immediately after the completion of the Transaction, Parent will be beneficially owned by the affiliates of Orient Hongtai Zhihe (Beijing) Investment Management Co., Ltd. (东方弘泰志合（北京）投资管理有限公司) (a subsidiary of Orient Securities Company Limited), ChangJiang Growth Capital Investment Co., Ltd. (长江成长资本投资有限公司) (a subsidiary of Changjiang Securities Company Limited) and Beijing HT Capital Investment Management Co., Ltd. (北京海桐资本投资管理有限公司) (collectively, the “Buyers”).

The Company’s board of directors (the “Board”) unanimously approved the Merger Agreement and the Transaction and resolved to recommend that the Company’s shareholders vote to authorize and approve the Merger Agreement and the Transaction.

The Transaction is subject to various closing conditions, including a condition that the Merger Agreement be authorized and approved by an affirmative vote of shareholders representing two-thirds or more of the voting power of the shares present and voting in person or by proxy as a single class at a meeting of the Company’s shareholders convened to consider the authorization and approval of the Merger Agreement. If completed, the Transaction will result in the Company becoming a privately-held company and its ADSs will no longer be listed on the Nasdaq Global Market.

The Company will furnish to the Securities and Exchange Commission (the “SEC”) a report on Form 6-K regarding the transaction, which will include the Merger Agreement. All parties desiring details regarding the Transaction are urged to review these documents, which will be available at the SEC’s website (http://www.sec.gov).

Duff & Phelps, LLC is serving as financial advisor to the Company. Kirkland & Ellis is serving as U.S. legal advisor to the Company and Guantao Law Firm and Maples and Calder are serving as PRC and Cayman Islands legal advisors to the Company, respectively.

Wilson Sonsini Goodrich & Rosati, P.C. is serving as U.S. legal advisor to the Buyers and King & Wood Mallesons and Conyers Dill & Pearman are serving as PRC and Cayman Islands legal advisors to the Buyers, respectively.

This announcement is neither a solicitation of proxies, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other materials that may be filed or furnished with the SEC should the proposed Transaction proceed.

About CMGE

CMGE is the largest publisher and a leading developer of mobile games in China with integrated capabilities across the mobile game value chain. Its fully integrated capabilities include the development, licensing, publishing, distribution and operation of mobile games, primarily in China. Its social games are mainly developed for Android and iOS-based smartphones. CMGE’s extensive distribution network includes its proprietary Game Center application, handset pre-installations, application stores and web platforms and mobile network operators. The offices are in Guangzhou, Shenzhen, Beijing, Chengdu, Shanghai, Hong Kong, Tokyo, Taipei and Seoul. The Company’s stock is traded on NASDAQ under the symbol CMGE. For more corporate and product information, please visit CMGE’s website at http://www.cmge.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. CMGE may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about CMGE’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Potential risks and uncertainties include, but are not limited to, uncertainties as to how CMGE’s shareholders will vote at the meeting of shareholders, the possibility that competing offers will be made, the possibility that various closing conditions to the Transaction may not be satisfied or waived and other risks discussed in CMGE’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of the press release, and CMGE undertakes no duty to update such information, except as required under applicable law.

CONTACT: For investor and media inquiries, please contact:
         China Mobile Games and Entertainment Group Limited
         Tel: +852 2700 6168
         E-mail: ir@cmge.com

(TISA) Names Content-driven Process Automation Exec. TIS Americas President

TEL AVIV, Israel and COLOGNE, Germany and PLANO, Texas, June 9, 2015  — Top Image Systems, Ltd. (Nasdaq:TISA), a global innovator of intelligent content processing solutions, today announced that, effective Tuesday June 2nd, Bob Fresneda has assumed the position of President, TIS Americas. Fresneda joined TIS to accelerate fulfillment of the Company’s goal to substantially expand its U.S. operations. Most recently serving as SVP, Region Americas & Asia Pacific for ReadSoft AB, which was acquired by Lexmark in 2014, Fresneda was responsible for growth of his region’s revenues to over 30 million USD. Following the Lexmark acquisition, he took responsibility for Worldwide Channel Sales for Lexmark Enterprise Software. Fresneda brings to TIS his proven ability to build highly profitable North American sales, professional services and support teams, strengthen U.S. brand presence and most important – expand market share.

Fresneda’s addition to the TIS global executive team at this juncture will aid TIS in exploiting the consolidation in current market conditions to further develop valuable global partnerships. In parallel, it will strengthen the Company’s leadership and market share in the Accounts Payable / Accounts Receivable sector and its strategic focus on cloud and mobile content capture, automation and end-to-end process automation solutions.

Fresneda brings to TIS strong experience in managing profit & loss, mergers and acquisitions and in growing from infancy a US subsidiary for a global organization; during his tenure, the US subsidiary led all subsidiaries in total revenue and profits, number of personnel, revenue growth and profit growth.

“After spending many years as a senior executive in a large global organization focused on financial process automation which has now been acquired to be a part of a large hardware, services and software organization, I am looking forward to making a fresh start within the creative management team of an agile, dynamic and innovative technology provider such as TIS, ” commented Bob Fresneda. “The process automation market, now merging mobile, cloud and on-premise technologies, is primed for growth. I believe that TIS has the expertise, strategic direction and high-performance platform that will drive the Company to a rapid increase in revenues and profits.

“TIS is extremely fortunate to be able to add Bob Fresneda’s business leadership and solid management skills to our executive management team. We are confident that Bob will be an effective asset in strategically accelerating our growth in the U.S., a market Top Image Systems is committed to building up in order to make a dramatic contribution to our short and long-term global performance. We offer Bob a big welcome to the TIS family and look forward to his impact in 2015 and beyond,” remarked Michael Schraeder, CEO, TIS.

About Top Image Systems

Top Image Systems™ (TIS™) Ltd. is a leading innovator of enterprise solutions for capturing and validating structured and unstructured content entering organizations from various sources and managing content-driven business processes. Whether originating from mobile, electronic, paper or other sources, TIS solutions automatically capture, process and deliver content across enterprise applications. TIS’ flagship eFLOW® platform and diverse business process and mobile image processing solutions are marketed in more than 40 countries through a multi-tier network of distributors, system integrators, value-added resellers and strategic partners. Visit the company’s website at http://www.TopImageSystems.com for more information.

Caution Concerning Forward-Looking Statements

Certain matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results expressed or implied in those forward looking statements. Words such as “will,” “expects,”, “anticipates,” “estimates,” and words and terms of similar substance in connection with any discussion of future operating or financial performance identify forward-looking statements. These statements are based on management’s current expectations or beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially including, but not limited to, risks in product development, approval and introduction plans and schedules, rapid technological change, customer acceptance of new products, the impact of competitive products and pricing, the lengthy sales cycle, proprietary rights of TIS and its competitors, risk of operations in Israel, government regulation, litigation, general economic conditions and other risk factors detailed in the Company’s most recent annual report on Form 20-F and other subsequent filings with the United States Securities and Exchange Commission. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: TIS Company Press Contact:
         Shelli Zargary
         Director of Corporate Marketing and Investor Relations
         shelli.zargary@topimagesystems.com
         +972 3 767 9114

         TIS Investors:
         James Carbonara
         Regional Vice President, Hayden IR
         james@haydenir.com
         + 1 646 755 7412

(SZYM) & Natura Announce Sales Agreement for Microalgae Oil

Natura Cosméticos S.A. (BM&FBOVESPA:NATU3) one of Latin America’s largest cosmetics and personal care products company, and Solazyme, Inc. (NASDAQ:SZYM), a renewable oils and ingredients company, announced today that after successfully completing testing and product validation phases over the past year using Solazyme’s oils, Natura is purchasing Solazyme’s high-performance AlgaPūr^TM Microalgae Oil, which will be incorporated into Natura’s multiple product lines.

Solazyme’s microalgae oils are produced in a matter of days using a fermentation process designed to produce oils of the highest purity, performance and sustainability. Some of the benefits of using AlgaPūr oils for skin care are higher hydration levels, a silky but not greasy skin feel, mildness on the skin, neutral color and odor, and improved shelf life.

Walfredo Linhares, General Manager of Solazyme Bunge Renewable Oils in Brazil, said, “We believe high performance and sustainability belong together. Natura is a leader in innovation and globally recognized for their sustainability efforts. We are very happy to work together to deliver better products for consumers and for our planet.”

Natura and Solazyme have been working together for two years on several projects on joint efforts to develop new formulations with Solazyme’s microalgae oils. “We are always looking for ingredients from renewable sources and technologies inspired in the nature, targeting low environmental impact processes and high performance solutions,” says Daniel Gonzaga, Director of Advanced Research of Natura. “Solazyme microalgae oil that will compose some of our products are a sustainable alternative for new formulations development,” he concludes.

Solazyme produces sustainable high performance ingredients for multiple markets and its joint venture facility is located in São Paulo State, in partnership with Bunge.

About Solazyme, Inc.

Solazyme, Inc. develops and sells high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, the world’s original oil producer, Solazyme creates innovative, sustainable, high-performance products. These include renewable oils and ingredients that serve as the foundation for healthier foods; high-performance industrial products; unique home and personal care solutions; and more sustainable fuels. Headquartered in South San Francisco, Solazyme’s mission is to solve some of the world’s biggest problems with one of the world’s smallest and earliest life forms: microalgae.

For additional information, please visit Solazyme’s website at www.solazyme.com.

About Natura

Founded in 1969, Natura is the biggest Brazilian multinational of cosmetics and health and beauty products. Leader in the direct sales industry in Brazil, it reported net revenue totaling R$ 7.4 billion in 2014, it has 7,000 employees, 1.7 million consultants and operations in Argentina, Bolivia, Chile, Mexico, Peru, Colombia and France.

Largest B Corp company in the world, it was the first publicly-held company to receive the certification, in December 2014, which reinforces its transparent and sustainable operations on social, environmental and economic aspects. The company’s structure is made up of plants in Cajamar (SP) and Benevides (PA), eight distribution centers in Brazil, one HUB in Itupeva, in addition to Research and Technology centers in São Paulo (SP), Manaus (AM) and New York (USA). It holds 65% of the Australian manufacturer of cosmetics Aesop, with stores in countries in Oceania, Asia, Europe and North America. Natura’s products can be purchased through Revista Natura (product catalog) or Rede Natura at www.redenatura.net. To find a Natura Consultant nearby, consumers can send a free SMS with the word for Natura 28128. For more information about the company, visit www.natura.com.br and check their profiles on the following social networks: Linkedin, Facebook, Twitter and YouTube.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization and production plans; meeting commercialization and technology targets; successful product trials and market acceptance of its products; and Solazyme’s ability to maintain its relationships with its partners. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing, ramping up and operating commercial manufacturing facilities; its ability to sell its products at a profit; delays related to construction, start-up and ramp-up of production facilities; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.

In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.

Solazyme, Inc.
Genet Garamendi, 650-780-4777
Corporate Communications
press@solazyme.com

(MARA) Wholly-Owned Subsidiaries Enter Into Settlement and License Agreement

(SAGE) Top-Line Data, Exploratory Trial of SAGE-547 in Postpartum Depression

Marked Improvement Demonstrated in HAM-D Scores in Patients with PPD Enrolled in Open-Label Trial

Plan to Initiate Placebo-Controlled Trial of SAGE-547 by Year End and Advance Novel Product Candidates for Potential Development

CAMBRIDGE, Mass., June 9, 2015  — SAGE Therapeutics (Nasdaq:SAGE) today announced top-line data from an exploratory clinical trial that indicate a statistically significant improvement from baseline in depression in four women with postpartum depression (PPD) within 24 hours after administration of intravenous SAGE-547 (paired t-test p=0.001). During the SAGE-547 treatment period, all four patients rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression (HAM-D). The patients had a mean HAM-D score of 26.5 at baseline and improved to a mean HAM-D score of 1.8 at the end of the 60-hour treatment period. All four patients also demonstrated consistent improvement as measured by the Clinical Global Impression-Improvement (CGI-I) scale. SAGE-547 was well-tolerated in all patients treated with no serious adverse events observed on therapy or during the 30-day follow-up period.

“Severe postpartum depression is a serious and debilitating form of major depressive disorder,” said Samantha Meltzer-Brody, M.D., Director of the Perinatal Psychiatry Program, University of North Carolina Center for Women’s Mood Disorders and Principal Investigator of the trial. “The signal of SAGE-547’s activity is highly encouraging for women and their families facing the devastating consequences of this condition. I look forward to continuing to study this treatment approach in the placebo-controlled trial.”

PPD is estimated to affect up to 20% of women following childbirth. The HAM-D scale is used by clinicians to rate the severity of 17 symptoms observed in depression, such as low mood, insomnia, agitation, anxiety and weight loss. A HAM-D rating of greater than 24.0 is considered severe and a score below 7.0 is considered symptom-free.

“These top-line results demonstrate an early but encouraging signal of activity in women with severe PPD and we believe further validate that the SAGE-547 mechanism of action has the potential to impact a broad range of disorders beyond epilepsy,” said Jeff Jonas, M.D., chief executive officer of SAGE. “Given the severity of this disorder and the strength of the initial signal, we plan to move from the initial open-label exploratory trial into a placebo-controlled trial to validate the activity signal as rapidly as possible. In parallel, we plan to advance several novel product candidates from our extensive compound library into development that we believe may be uniquely suited for the treatment of this devastating disorder.”

The exploratory open-label trial recruited women with PPD for treatment with a proprietary dosing schedule of SAGE-547 as an adjunctive therapy, a therapy combined with current therapeutic approaches. The trial was designed to provide data regarding safety, tolerability, pharmacokinetics and the acute effect of SAGE-547 on depressive symptoms as measured by the HAM-D and CGI-I. All of the patients enrolled had a Major Depressive Episode, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and were treated as inpatients. All four patients had an inadequate response to prior antidepressant therapy. The initial trial planned to enroll up to 15 patients or until 10 patients were deemed to be evaluable, whichever occurred first, aged 18 to 45 years, but after the consistent responses observed, the initial findings justified accelerating the program into a placebo-controlled trial.

SAGE-547 was well-tolerated with no serious adverse events reported during the treatment and follow-up periods and no discontinuations due to adverse events. A total of 14 adverse events were reported in four patients. The only adverse event reported in more than one patient was sedation, observed in two patients.

“I would like to thank these patients for participating in the trial and the nurses, physicians and staff at the Perinatal Psychiatry Inpatient Unit at UNC Neurosciences Hospital, along with our clinical team for the rapid completion of this first phase of clinical testing,” added Stephen Kanes, M.D., Ph.D., chief medical officer of SAGE. “Given that PPD has been associated with abnormalities of allopregnanolone levels, we believe this disorder represents an opportunity to evaluate SAGE-547’s mechanism of action in this patient population where there is a significant need for new treatment options.”

About SAGE-547

SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA_A receptors.   GABA_A receptors are widely regarded as validated drug targets for a variety of disorders, with decades of research and multiple approved drugs targeting these receptor systems. SAGE-547 is an intravenous agent entering Phase 3 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of super-refractory status epilepticus (SRSE), as well as in exploratory development for the treatment of essential tremor and postpartum depression. SAGE plans to begin enrollment of its planned Phase 3 clinical trial, called the STATUS Trial, in mid-2015. SAGE-547 has been granted both Fast Track and orphan drug designations by the U.S. Food and Drug Administration (FDA) for the treatment of SRSE. The active pharmaceutical ingredient for SAGE-547 has been contributed under agreement by the Regents of the University of California and the University of California, Davis.

About Postpartum Depression

Postpartum Depression (PPD) is distinct and readily identified form of depressive disorder estimated to affect up to 20% of women following childbirth^1,2. PPD may have devastating consequences for a woman and for her family, which may include depressed mood and/or loss of interest in her newborn, and associated symptoms of depression such as loss of appetite, difficulty sleeping, motor challenges, lack of concentration, loss of energy, poor self-esteem and suicidality. PPD is reported to be the most under-diagnosed obstetric complication in the U.S.³ and there is a continued need for improved pharmacological therapy for PPD.

About SAGE Therapeutics

SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. SAGE’s lead program, SAGE-547, is entering Phase 3 clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the Company is developing in its portfolio of potential anti-seizure medicines. SAGE’s proprietary chemistry platform has generated multiple new compounds that target GABA_A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com.

Forward-Looking Statements

Various statements in this release concerning SAGE’s future expectations, plans and prospects, including without limitation, SAGE’s expectations regarding SAGE-547 as a treatment for SRSE, essential tremor and severe postpartum depression, statements concerning the potential safety and efficacy of SAGE-547 and durability of response, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In addition, it should be noted that there is limited data concerning the safety and efficacy of SAGE-547. These data may not be repeated or observed in ongoing or future studies involving SAGE-547 or SAGE’s other product candidates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE’s ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE’s ability to manage operating expenses, SAGE’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in SAGE’s annual report on Form 10-K for the fiscal year ended December 31, 2014 and quarterly report on Form 10-Q for the quarter ended March 31, 2015, as well as discussions of potential risks, uncertainties, and other important factors in SAGE’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE’s views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements. 

¹ O’Hara MW, Wisner KL. Perinatal mental illness: definition, description and aetiology. Best Pract Res Clin Obstet Gynaecol 2014;28(1):3-12. doi: 10.1016/j.bpobgyn.2013.09.002

² Gavin NI, Gaynes BN. Perinatal Depression A Systematic Review of Prevalence and Incidence. Obstetrics & Gynecology 12/2005; 106(5 Pt 1):1071-83. doi: 10.1097/01.AOG.0000183597.31630.db

³ Earls MF; Committee on Psychosocial Aspects of Child and Family Health American Academy of Pediatrics. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics 2010;126(5):1032-9. doi: 10.1542/peds.2010-2348

CONTACT: Investor Contact:
         Paul Cox, SAGE Therapeutics
         paul.cox@sagerx.com
         617-299-8377

         Media Contact:
         Dan Budwick, Pure Communications
         dan@purecommunicationsinc.com
         973-271-6085

(LPTH) Supplies Infrared Molded Optics for Firefighting Thermal Imaging Cameras

(NAVB) Reports Positive Lymphoseek® Breast Cancer Comparative Results

Navidea Biopharmaceuticals (NYSE MKT: NAVB), announced that results from an investigator-initiated, comparative study of Lymphoseek® (technetium Tc 99m tilmanocept) injection versus filtered Tc-99m Sulfur Colloid (fTcSC) measuring injection site pain in patients with breast cancer undergoing lymphoscintigraphy were presented at the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. The results of the randomized, double-blinded trial, led by Anne Wallace, M.D., professor of surgery at University of California, San Diego School of Medicine, highlighted that fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek.

In preparation for Sentinel Lymph Node Biopsy in breast cancer and other cancers, lymphatic pathways are mapped using a procedure called lymphoscintigraphy. “Patients often fear this procedure given the evidence of injection pain from some radiotracers,” said Dr. Wallace, who is also director of the Comprehensive Breast Health Center at UC San Diego Moores Cancer Center. “This study of tilmanocept demonstrated, with patient-reported data, a significantly reduced level of post-injection associated pain compared with use of an fTcSC tracer. Along with its other desirable performance characteristics, surgeons now have a reliable tool that can potentially play an important role in improved patient comfort and management.”

“This investigator-initiated study is of particular importance as it continues to reinforce the clinical value of Lymphoseek,” said Michael Tomblyn, M.D., Navidea’s Executive Medical Director. “While previous studies have reported on Lymphoseek efficacy and ongoing safety, these results further illustrate both the clinical utility and clear benefits to both surgical oncologists and patients.”

The poster presentation entitled, ”A Randomized Double-Blinded Comparison of Injection Site Pain of Tc-99m Tilmanocept versus Filtered Tc-99m Sulfur Colloid in Patients Undergoing Lymph Node Mapping for Breast Cancer” showed results of the randomized, double-blind clinical trial comparing post-injection site pain using fTcSC versus Lymphoseek in 52 [(27) fTcSC and (25) Lymphoseek] breast cancer patients undergoing lymphoscintigraphy. Pain was evaluated with a visual analogue scale and short form McGill Pain Questionnaire at 1, 2, 3, 4, 5, 15 and 30 minutes post-injection. Analysis of the data indicates baseline pain scores were similar between groups. At one minute post-injection, patients receiving fTcSC experienced a mean change in pain of 16.8mm (standard deviation (SD) 19.5) compared to 0.2mm (SD 7.3) in the Lymphoseek group (p =0.0002). Overall, patients receiving Lymphoseek experienced statistically significant less change in pain scores compared to patients receiving fTcSC at 1-3 minutes post-injection.

About Lymphoseek

Lymphoseek^® (technetium Tc 99m tilmanocept) injection is the first and only FDA-approved receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek is approved by the U.S. Food and Drug Administration (FDA) for use in solid tumor cancers where lymphatic mapping is a component of surgical management and for guiding sentinel lymph node biopsy in patients with clinically node negative breast cancer, melanoma or squamous cell carcinoma of the oral cavity. Lymphoseek has also received European approval in imaging and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma of the oral cavity.

Accurate diagnostic evaluation of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. Overall in the U.S., solid tumor cancers may represent up to 1.2 million cases per year. The sentinel node label in the U.S. and Europe may address approximately 235,000 new cases of breast cancer, 76,000 new cases of melanoma and 45,000 new cases of head and neck/oral cancer in the U.S., and approximately 367,000 new cases of breast cancer, 83,000 new cases of melanoma and 55,000 new cases of head and neck/oral cancer diagnosed in Europe annually.

Lymphoseek Indication and Important Safety Information

Lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

• Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.
• Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).

FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT:
WWW.LYMPHOSEEK.COM

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek^® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150608006395/en/

(SYMX) Commissioning Phase at 1st of 3 (ACH) Syngas Gasification Plants

$23 Million Technology and Equipment Supply for Three New Clean Coal Natural Gas Replacement Projects Featuring SES Gasification Technology is First Order Secured by SES’ China JV, Tianwo-SES Clean Energy Technologies Company

HOUSTON, June 8, 2015  — Synthesis Energy Systems, Inc. (SES) (Nasdaq:SYMX), a global energy and gasification technology company enabling clean, high-value energy and chemical products from multiple feedstocks, announced that the first of three previously announced industrial syngas gasification plants from its Tianwo-SES Joint Venture has entered the commissioning phase. The plant, in Zibo City, Shandong Province, China, is owned and operated by Aluminum Corporation of China Limited (NYSE:ACH) (HKEx:2600) (SSE:601600), and utilizes two SES Gasification Technology systems supplied by Tianwo-SES. These gasification systems are uniquely suited to generate clean and economical syngas from local, low-grade lignite coal which will replace the purchase of more expensive natural gas. The Shandong facility is projected to enter commercial operation this year. The two additional Aluminum Corporation of China plants, in Shanxi and Henan Provinces, are currently under construction in a phased, fast-track timeline. Once all three projects enter commercial operation, the installed base for SES Gasification Technology will expand from five to 12 gasification systems in operation in China.

Total construction order commitments of $105 million (650 million Yuan) for the three projects were announced in December 2014 between Aluminum Corporation of China, China’s largest alumina and primary aluminum producer, and Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd. (ICCDI). ICCDI is the general contractor supplying all the engineering, construction and balance of plant equipment for the three projects. The total order value for these projects to Tianwo-SES for technology and equipment supply from ICCDI, a subsidiary of Suzhou Thvow Technology Co., Ltd. (STT) (Shenzhen listing code:002564), is expected to be $23 million. Tianwo-SES Clean Energy Technologies Co., Ltd. (Tianwo-SES) is SES’s joint venture with STT.

“Late last year, China Shandong Aluminum Industry Branch, Henan Branch and Shanxi Aluminum Co., Ltd. contracted ICCDI to build these three important projects. Through great cooperation of all the parties, the Shandong Aluminum Project is now the first to begin commissioning and is driving for fast completion. Securing these three major China Aluminum projects is taking Suzhou Thvow Technology from a high-end equipment manufacturer to now include technology, research and development, and engineering services, to provide one total high-tech package solution for clean energy. With our partner SES, our Tianwo-SES company is driving to become a world leader in clean energy technology,” stated STT Chairman Chen Yu Zhong.

“The ICCDI and Tianwo-SES teams are to be commended for accomplishing this very fast project execution schedule and achieving this six-month commissioning milestone. These first orders are expected to deliver the first significant revenues to Tianwo-SES, and the speed and ease of construction demonstrates the turnkey simplicity of deploying the advanced SES Gasification Technology,” said DeLome Fair, President of SES Technologies, LLC. “These plants are expected to be the model for future projects in the growing natural gas replacement market in China. Based on our analysis, we believe the estimated cost savings to Aluminum Corporation of China at the Shandong plant alone will be in the order of $50,000 per day.

“We are making good traction in China and congratulate our China JV partner, Suzhou Thvow Technology, on securing the award for these groundbreaking projects. We believe replacement gas, which enables Growth With Blue Skies, represents a significant market segment for new plants and the retrofit of large numbers of existing facilities in the region, supplying clean and economical fuel gas to numerous industries. Tianwo-SES reports seven similar projects in its growing pipeline,” added Ms. Fair.

About Synthesis Energy Systems, Inc.

Synthesis Energy Systems (SES) is a Houston-based technology company focused on bringing clean high-value energy to developing countries from low-cost and low-grade coal and biomass through its proprietary gasification technology based upon U-Gas®, licensed from the Gas Technology Institute. The SES Gasification Technology enables Growth With Blue Skies, and greater fuel flexibility for both large-scale and efficient small- to medium-scale operations close to fuel sources. Fuel sources include low-rank, low-cost high ash, high moisture coals, which are significantly cheaper than higher grade coals, many coal waste products, and biomass feedstocks. For more information, please visit: www.synthesisenergy.com.

About Tianwo-SES Clean Energy Technologies Co., Ltd. 

Tianwo-SES Clean Energy Technologies Co., Ltd. (Tianwo-SES) is a joint venture between Synthesis Energy System’s wholly owned subsidiary, SES Asia Technologies, Ltd. and Suzhou Thvow Technology Co., Ltd. (STT). The joint venture was formed in 2014 to bring clean energy technologies and turnkey SES gasification systems to China and select Asian markets, combining SES’s advanced proprietary gasification technology with the market reach of one of China’s leading coal-chemical equipment manufacturers. The joint venture’s target markets also include Indonesia, Malaysia, Mongolia, the Philippines, and Vietnam. SES owns 35%, and STT owns 65%, of Tianwo-SES. For more information on STT, visit: http://www.thvow.com/main_en.

About Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd.       

Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd. (ICCDI) is based on the restructuring of Coking Design Institute of Shanghai Pacific Chemical Company affiliated Shanghai Huayi Group which is the largest and oldest chemical group under Shanghai municipal government. On October 15, 2010, ICCDI was transformed from a state-owned company into private one, and is 95% owned by Suzhou Thvow Tianwo Technology Co., Ltd. (Thvow). ICCDI is a Class-A design institute with class-A license in chemicals design, class-A license in engineering consulting and class-A license in Evaluation on energy saving. For more information on ICCDI, visit: http://www.iccdi.com.cn/en/.

About Aluminum Corporation of China Limited

Aluminum Corporation of China Limited (CHALCO) is China’s largest alumina and primary aluminum producer and the world’s second largest alumina producer. CHALCO was established as a joint stock limited company in the People’s Republic of China on September 10, 2001 by way of promotion by Aluminum Corporation of China (CHINALCO), Guangxi Investment (Group) Co., Ltd. and Guizhou Provincial Materials Development and Investment Corporation. With a registered capital of RMB 11.049 billion, CHALCO owns ten branches, one research institute, and 12 subsidiaries. It was listed on the New York Stock Exchange, Inc. and the Hong Kong Stock Exchange on December 11 and 12, 2001, respectively (NYSE: ACH; Hong Kong listing code: 2600; Shanghai Stock Exchange listing code: 601600). For more information on CHALCO, visit: http://www.chalco.com.cn/zlgfen/index.htm

SES Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the ability of our ZZ joint venture to effectively operate XE’s methanol plant and produce methanol; the ability of our project with Yima to produce earnings and pay dividends; our ability to develop and expand business of the Tianwo-SES joint venture in the joint venture territory; our ability to successfully partner our technology business; our ability to develop our power business unit and marketing arrangement with GE and our other business verticals, including DRI steel, through our marketing arrangement with Midrex Technologies, and renewables; our ability to successfully develop the SES licensing business; events or circumstances which result in an impairment of assets, including, but not limited to, at our ZZ Joint Venture; our ability to reduce operating costs; our ability to make distributions and repatriate earnings from our Chinese operations; our limited history, and viability of our technology; commodity prices, including in particular methanol, and the availability and terms of financing; our ability to obtain the necessary approvals and permits for future projects; our ability to raise additional capital, if any, and our ability to estimate the sufficiency of existing capital resources; the sufficiency of internal controls and procedures; and our results of operations in countries outside of the U.S., where we are continuing to pursue and develop projects. Although SES believes that in making such forward-looking statements our expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected by us. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Contact:

MDC Group
Investor Relations:
David Castaneda
Arsen Mugurdumov
414.351.9758
IR@synthesisenergy.com

Media Relations:
Susan Roush
747.222.7012
PR@synthesisenergy.com

(SEED) CEO Will Present in an Investor Meeting at Wells Fargo Securities

BEIJING, June 8, 2015  — Origin Agritech Limited (NASDAQ GS: SEED) (“Origin”, or the “Company”), a technology-focused supplier of crop seeds in China, today announced that Dr. Gengchen Han, Chairman and CEO of Origin, will present in an investor’s meeting organized by Wells Fargo Securities on June 16^th, 2015. In his presentation, Dr. Han is expected to discuss the strategic direction of new Origin Agritech and company’s capabilities in biotech corn seed development, corn seed breeding technologies, and seed production & distribution. His presentation materials will be filed with SEC before the meeting.

This investor’s meeting will be hosted by Wells Fargo Securities in Midtown Manhattan, New York City and will start at noon on June 16th, 2015. For interested investors, please contact Noelle Ulrich of Wells Fargo at Noelle.L.Ulrich@wellsfargo.com or Investor Relation of Origin Agritech at IR@originseed.com.cn.

About Origin

Founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, Origin Agritech Limited (NASDAQ GS: SEED) is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies in China, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please log on to the Company’s website at: www.originseed.com.cn.

Forward Looking Statement

This release contains forward-looking statements. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to differ materially from those implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “targets,” “goals,” “projects,” “continue,” or variations of such words, similar expressions, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Neither we nor any other person can assume responsibility for the accuracy and completeness of forward-looking statements. Important factors that may cause actual results to differ from expectations include, but are not limited to, those risk factors discussed in Origin’s filings with the SEC including its annual report on Form 20-F. We undertake no obligation to revise or update publicly any forward-looking statements for any reasons.

CONTACT:
Origin Agritech Limited
James Chen
Chief Financial Officer
james.chen@originseed.com.cn

Origin Agritech Investor Relations
IR@originseed.com.cn
+86-10-5890-7536